脉络膜上曲安奈德对眼压的影响:系统回顾和荟萃分析。

IF 2.3 Q2 OPHTHALMOLOGY Therapeutic Advances in Ophthalmology Pub Date : 2024-02-05 eCollection Date: 2024-01-01 DOI:10.1177/25158414241228671
Altamash Shahriyar Ghazanfar, Aly Hamza Khowaja, Haroon Tayyab
{"title":"脉络膜上曲安奈德对眼压的影响:系统回顾和荟萃分析。","authors":"Altamash Shahriyar Ghazanfar, Aly Hamza Khowaja, Haroon Tayyab","doi":"10.1177/25158414241228671","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Triamcinolone acetonide is a synthetic corticosteroid with multiple ocular uses. Like other corticosteroids, it too is associated with ocular side effects such as increased intraocular pressure (IOP), glaucoma and cataracts. Suprachoroidal administration of triamcinolone is hoped to reduce the ocular side effects of the drug, especially rises in IOP. Our systematic review and meta-analysis aims to study this phenomenon.</p><p><strong>Objectives: </strong>The purpose of this study was to evaluate the effect of suprachoroidal triamcinolone injections on IOP.</p><p><strong>Design: </strong>Systematic review and meta-analysis.</p><p><strong>Methods: </strong>We utilized the Medline, Scopus and Cochrane databases for this review. Studies published till June 2023, which fulfilled the eligibility criteria, were included. Studies in the English language with adult participants who were administered suprachoroidal triamcinolone without any concurrent intervention were included, whereas studies that did not report the mean and standard deviation for IOP were excluded. The outcome of interest was IOP at 1, 3 and 6 months post-suprachoroidal triamcinolone injection. IOP values from included studies were extracted onto Review Manager version 5.4 for analysis.</p><p><strong>Results: </strong>Our search yielded 104 results, from which 22 papers were shortlisted for full-text screening. Finally, 12 studies were included in the analysis. Our analysis suggests a statistically significant increase in IOP in the first month after suprachoroidal triamcinolone injection but no significant differences at 3 and 6 months post-injection as compared to baseline.</p><p><strong>Conclusion: </strong>Elevated IOP at 1 month post-injection must be considered when using suprachoroidal triamcinolone and adequate safety measures must be taken. However, the absence of a significant rise at 3 and 6 months post-injection indicates that this modality is safer than other existing drug delivery methods.</p><p><strong>Trial registration: </strong>Registered with the Research Registry with the unique identifying number 'reviewregistry1656.' https://www.researchregistry.com/browse-the-registry#registryofsystematicreviewsmeta-analyses/registryofsystematicreviewsmeta-analysesdetails/648eefe65b6523002995eb21/.</p>","PeriodicalId":23054,"journal":{"name":"Therapeutic Advances in Ophthalmology","volume":"16 ","pages":"25158414241228671"},"PeriodicalIF":2.3000,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845981/pdf/","citationCount":"0","resultStr":"{\"title\":\"Effect of suprachoroidal triamcinolone on intraocular pressure: a systematic review and meta-analysis.\",\"authors\":\"Altamash Shahriyar Ghazanfar, Aly Hamza Khowaja, Haroon Tayyab\",\"doi\":\"10.1177/25158414241228671\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Triamcinolone acetonide is a synthetic corticosteroid with multiple ocular uses. Like other corticosteroids, it too is associated with ocular side effects such as increased intraocular pressure (IOP), glaucoma and cataracts. Suprachoroidal administration of triamcinolone is hoped to reduce the ocular side effects of the drug, especially rises in IOP. Our systematic review and meta-analysis aims to study this phenomenon.</p><p><strong>Objectives: </strong>The purpose of this study was to evaluate the effect of suprachoroidal triamcinolone injections on IOP.</p><p><strong>Design: </strong>Systematic review and meta-analysis.</p><p><strong>Methods: </strong>We utilized the Medline, Scopus and Cochrane databases for this review. Studies published till June 2023, which fulfilled the eligibility criteria, were included. Studies in the English language with adult participants who were administered suprachoroidal triamcinolone without any concurrent intervention were included, whereas studies that did not report the mean and standard deviation for IOP were excluded. The outcome of interest was IOP at 1, 3 and 6 months post-suprachoroidal triamcinolone injection. IOP values from included studies were extracted onto Review Manager version 5.4 for analysis.</p><p><strong>Results: </strong>Our search yielded 104 results, from which 22 papers were shortlisted for full-text screening. Finally, 12 studies were included in the analysis. Our analysis suggests a statistically significant increase in IOP in the first month after suprachoroidal triamcinolone injection but no significant differences at 3 and 6 months post-injection as compared to baseline.</p><p><strong>Conclusion: </strong>Elevated IOP at 1 month post-injection must be considered when using suprachoroidal triamcinolone and adequate safety measures must be taken. However, the absence of a significant rise at 3 and 6 months post-injection indicates that this modality is safer than other existing drug delivery methods.</p><p><strong>Trial registration: </strong>Registered with the Research Registry with the unique identifying number 'reviewregistry1656.' https://www.researchregistry.com/browse-the-registry#registryofsystematicreviewsmeta-analyses/registryofsystematicreviewsmeta-analysesdetails/648eefe65b6523002995eb21/.</p>\",\"PeriodicalId\":23054,\"journal\":{\"name\":\"Therapeutic Advances in Ophthalmology\",\"volume\":\"16 \",\"pages\":\"25158414241228671\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2024-02-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10845981/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Therapeutic Advances in Ophthalmology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/25158414241228671\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/25158414241228671","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:曲安奈德是一种人工合成的皮质类固醇,在眼部有多种用途。与其他皮质类固醇一样,它也与眼部副作用有关,如眼压升高、青光眼和白内障。人们希望通过在脉络膜上注射曲安奈德来减少该药物对眼睛的副作用,尤其是眼压的升高。我们的系统综述和荟萃分析旨在研究这一现象:本研究旨在评估脉络膜上腔注射曲安奈德对眼压的影响:系统综述和荟萃分析:方法:我们利用 Medline、Scopus 和 Cochrane 数据库进行综述。我们纳入了截至 2023 年 6 月发表的符合资格标准的研究。纳入的研究均为英语,且成年参与者均接受了脉络膜上曲安奈德治疗,未同时进行任何干预,而未报告眼压平均值和标准差的研究则被排除在外。研究结果为注射脉络膜上曲安奈德后 1、3 和 6 个月的眼压。将纳入研究的眼压值提取到 Review Manager 5.4 版进行分析:我们的搜索结果共产生 104 篇论文,从中筛选出 22 篇论文进行全文筛选。最后,12 项研究被纳入分析。我们的分析表明,在注射脉络膜上曲安奈德后的第一个月,眼压有统计学意义上的显著升高,但注射后 3 个月和 6 个月与基线相比没有显著差异:结论:在使用脉络膜上腔三苯氧胺时,必须考虑到注射后 1 个月的眼压升高,并采取适当的安全措施。不过,注射后 3 个月和 6 个月的眼压没有明显升高,表明这种方式比其他现有给药方法更安全:已在研究注册中心注册,唯一识别码为 "reviewregistry1656"。https://www.researchregistry.com/browse-the-registry#registryofsystematicreviewsmeta-analyses/registryofsystematicreviewsmeta-analysesdetails/648eefe65b6523002995eb21/。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Effect of suprachoroidal triamcinolone on intraocular pressure: a systematic review and meta-analysis.

Background: Triamcinolone acetonide is a synthetic corticosteroid with multiple ocular uses. Like other corticosteroids, it too is associated with ocular side effects such as increased intraocular pressure (IOP), glaucoma and cataracts. Suprachoroidal administration of triamcinolone is hoped to reduce the ocular side effects of the drug, especially rises in IOP. Our systematic review and meta-analysis aims to study this phenomenon.

Objectives: The purpose of this study was to evaluate the effect of suprachoroidal triamcinolone injections on IOP.

Design: Systematic review and meta-analysis.

Methods: We utilized the Medline, Scopus and Cochrane databases for this review. Studies published till June 2023, which fulfilled the eligibility criteria, were included. Studies in the English language with adult participants who were administered suprachoroidal triamcinolone without any concurrent intervention were included, whereas studies that did not report the mean and standard deviation for IOP were excluded. The outcome of interest was IOP at 1, 3 and 6 months post-suprachoroidal triamcinolone injection. IOP values from included studies were extracted onto Review Manager version 5.4 for analysis.

Results: Our search yielded 104 results, from which 22 papers were shortlisted for full-text screening. Finally, 12 studies were included in the analysis. Our analysis suggests a statistically significant increase in IOP in the first month after suprachoroidal triamcinolone injection but no significant differences at 3 and 6 months post-injection as compared to baseline.

Conclusion: Elevated IOP at 1 month post-injection must be considered when using suprachoroidal triamcinolone and adequate safety measures must be taken. However, the absence of a significant rise at 3 and 6 months post-injection indicates that this modality is safer than other existing drug delivery methods.

Trial registration: Registered with the Research Registry with the unique identifying number 'reviewregistry1656.' https://www.researchregistry.com/browse-the-registry#registryofsystematicreviewsmeta-analyses/registryofsystematicreviewsmeta-analysesdetails/648eefe65b6523002995eb21/.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.50
自引率
0.00%
发文量
44
审稿时长
12 weeks
期刊最新文献
The efficacy and safety of continuous blanket suture for severe recurrent pterygium with symblepharon. The experiences of visually impaired military veterans with Charles Bonnet syndrome. Are depression, anxiety and loneliness associated with visual hallucinations in younger adults with Charles Bonnet syndrome? Clinical characteristics of allergic conjunctivitis in the Southern region of Saudi Arabia: a cross-sectional study. Optical coherence tomography angiography to assess for retinal vascular changes in Neuro-Sjögren.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1